There are many factors that can affect the pharmacokinetics (PK) of drugs. Pathophysiological changes from disease states can alter the mechanisms that control the PK of antiretrovirals (ARVs), direct-acting antivirals (DAAs), and addiction treatment medications. Drug-drug interaction pathways of certain ARVs and DAAs can be very complex, with agents being substrates, inhibitors, or inducers of multiple metabolic and transporter pathways. Buprenorphine and methadone may be used in HIV-and hepatitis C virus (HCV)-infected patients and may also be affected by drug interactions. Current research is focused on novel PK analyses, which aim to describe the PK of agents within organs that host the infection of interest, such as within hepatocytes during treatment for HCV. Modeling techniques allow for the prediction of drug PK in specific organs and the plasma compartment. This review will provide a summary of these areas while exploring PK considerations for ARVs, DAAs, and addiction treatment medications.
Multiple factors can contribute to pharmacokinetic (PK) drug interactions. If drugs are administered orally, several possible mechanisms can modulate PK from within the gut, such as gastrointestinal absorption (eg, chelation, changes in pH, motility alterations), membrane transporters, and metabolism in the gut wall. When a drug is transferred via the portal vein to the liver, hepatic processes that affect PK can occur, consisting of additional uptake and efflux membrane transporters, metabolism, elimination in the bile, and enterohepatic cycling.
Pathophysiological changes from disease states can alter the mechanisms that control the PK of antiretrovirals (ARVs), direct-acting antivirals (DAAs), and addiction treatment medications. When drug-drug interaction studies are conducted in healthy volunteers, this assumes that the PK profiles seen in these healthy adults will be comparable to those in patients with the disease state of interest. 1 However, this assumption has certain limitations. HIV and hepatitis C virus (HCV) infections can affect the small intestine and liver, 2, 3 which are major sites involved in drug absorption, transport, metabolism, and elimination. 4 Possible pathophysiological changes in transporter and metabolic function from HIV and HCV are summarized in Table 1 . The possibility that individuals with disease may exhibit altered PK parameters has been discussed. 9 For example, HIV-infected patients demonstrate decreased relative bioavailability of efavirenz compared with healthy subjects. 10 It has also been reported that subjects coinfected with HIV/HCV with or without cirrhosis had significantly lower oral nelfinavir clearance than HIV-monoinfected subjects. 11 In a study of HIV+ adult men and controls with comparable weight, body mass index, and estimated creatinine clearance, a significant difference in mean plasma fluconazole clearance was found between HIV+ subjects with the lowest CD4+ T-cell count, HIV+ subjects with higher CD4+ T-cell counts and controls.
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Drug Interactions in HAART Era and Today
Highly active antiretroviral therapy (HAART) was first introduced in the 1990s and has revolutionized the treatment of HIV, greatly improving the morbidity and mortality associated with HIV infection. However, combining these medications with other agents also came with an increased risk for drug interactions, based on the different PK effects each drug had on the others. In addition, HAART required a large pill burden, with certain drugs having specific administration requirements. These concerns have been somewhat reduced as single daily medications have become available in coformulated combinations.
Currently, with the advancement in HCV therapies and increased rate of HIV/HCV coinfection being simultaneously treated, new drug-drug interactions have become a concern. 13 The effects may manifest in changes in systemic or tissue exposure of the DAA or ARV. Potentially this could cause increases in exposure, resulting in adverse or toxic effects, or decreases in efficacy. In addition, these interactions could extend to concomitant medications commonly used in this patient population, such as antihypertensives, statins, and opioid maintenance therapy.
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Factors Influencing Intrahepatic Drug Concentrations
Currently research interest has been extended beyond measuring only plasma concentrations, because it has been realized that this may not be representative of the drug that is present at the site of action or tissue of interest. 15, 16 Membrane transporters are important for hepatic uptake and efflux, potentially affecting plasma or hepatic drug concentration. 15 The question arises about whether to target plasma or liver concentrations for deciding DAA dosing and the importance of understanding information gained from hepatic drug sampling in addition to plasma pharmacokinetics. 17 
Clinical Pharmacology of New HCV DAAs
The interaction pathways of some current DAAs can be rather complex, with agents being substrates, inhibitors, or inducers of multiple metabolic and transporter pathways. 13 In addition, DAAs with different mechanisms of action are given in combination to increase efficacy and decrease the chance of resistant virus emerging. Importantly, these combinations of DAAs have allowed for the removal of interferon from HCV regimens, 18 thus limiting the toxicity and burden of injections associated with this agent. When ARVs and DAAs are combined to treat HIV/HCV coinfected populations, these patients could take at least 5 different medications to treat these 2 infections. Notably, these patients may also have multiple comorbidities that require additional pharmacotherapy. Therefore, the net effect from these individual drug interaction pathways results in the pharmacologic/toxic effect that is observed within an individual.
Complexities with Substance Abuse
In a study examining the influence of active substancerelated disorder (SRD) in HIV subjects receiving combination antiretroviral therapy, 19 subjects were divided into those with SRD and those without. 19 Pharmacokinetic evaluation was performed by sampling ARV trough concentrations and additional samples after an observed dose. It was noted that those subjects with SRD were more likely to have efavirenz or protease inhibitor trough concentrations below the desired range (P = .048). 19 At the time of therapeutic drug monitoring, patients with active SRD had a significantly lower percentage of those with HIV-1 RNA < 75 copies/mL compared with those without active SRD (P = .044); however, in a multivariate linear regression model known substance use was not significantly associated with CD4+ cell count and HIV RNA < 75 copies/mL at study entry.
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Drug Interactions with Addiction Treatment Medications
Buprenorphine and methadone are addiction treatment medications recommended to treat opioid addiction in HIV-and HCV-infected patients. In vitro, buprenorphine and methadone are both substrates of cytochrome P450 3A4, with methadone also primarily being metabolized by CYP2B6. 20, 21 Thus, these agents may be subject to potential drug interactions with ARV or DAA regimens that modulate these metabolic enzymes. Caution is warranted, and understanding possible interactions is necessary when these drugs are co-administered. Investigation of buprenorphine and methadone drug interactions with ARVs has been extensive and reported in the literature.
22-25
Pharmacokinetic Analysis Approaches
Traditional PK analysis consists of the estimation of PK parameters from intensive drug concentration sampling over time. Population pharmacokinetic modeling is a method that can use not only intensive data, but also data from sparse sampling strategies 26 that cannot be used for traditional PK analysis. 26 Population pharmacokinetics is used to evaluate the pharmacokinetic variability seen in individuals within a population. 27 However, a limitation to population pharmacokinetic modeling is that this method of analysis cannot be used to anticipate new drug-drug interactions in conditions in which multiple medications are given.
Another modeling approach, called physiologically based pharmacokinetic (PBPK) modeling, estimates parameters based on physiology, with models containing multiple compartments that correspond to organs within the body that are connected using physiologic blood flow rates. 28 PBPK models can estimate traditional PK parameters 28 while also accounting for pathophysiological changes that occur during a disease state of interest to predict the pharmacokinetic effect. 28 Also, in vitro data can be extrapolated to in vivo and used to inform these models. 29 These PBPK models can incorporate information from various sources and predict the PK of drug(s) in various situations, populations, or disease states. 28 
Pharmacogenomics
Using pharmacogenomics to tailor patients' pharmacotherapy is a growing field but is still in its infancy. 30 Looking at differences in gene expression can be examined as a covariate to explain differences in treatment response or adverse outcomes. In a study examining the effect of single-nucleotide polymorphisms (SNPs) for the gene encoding the delta-opioid receptor, the association of the genetic effect with buprenorphine treatment outcome in men and women was examined separately. An association between certain SNPs and buprenorphine treatment outcome was found for women: depending on the genotype, there was a significantly worse outcome; however, validation is required in an independent study. 31 In a study of 366 Asian subjects who were on maintenance methadone treatment, researchers examined a matrix of genetic variants from CYP2C19, CYP2B6, and CYP3A4 polymorphisms. It was found that the methadone dose was significantly influenced by allelic variants associated with the CYP2C19 gene.
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Conclusion
The pharmacokinetic interactions of ARV, DAAs, and addiction therapy are complex, potentially leading to alterations in drug concentrations and treatment outcomes with certain agents. Because of the high potential for drug interactions, patient medications should be closely examined prior to HCV treatment, including attention to addiction treatment medications. Reevaluation of a patient's medication list should be performed after the completion of DAA therapy.
Liver-sampling strategies may advance virologic and pharmacologic studies as well as identify drug interactions. It is important to be cognizant of possible tissue uptake/efflux and the site of action of the drug and to remember that plasma pharmacokinetics may not be representative of drug concentration in the tissue of interest.
Finally, a variety of modeling and analysis tools are available to help to answer the question of interest. The choice of which tool to use should be based on the study design, type of data that will be collected, and the question that is to be answered.
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